CN101244137B - Medicament for treating pulmonitis, and high fever, lower fever, and preparation method - Google Patents
Medicament for treating pulmonitis, and high fever, lower fever, and preparation method Download PDFInfo
- Publication number
- CN101244137B CN101244137B CN2008100078937A CN200810007893A CN101244137B CN 101244137 B CN101244137 B CN 101244137B CN 2008100078937 A CN2008100078937 A CN 2008100078937A CN 200810007893 A CN200810007893 A CN 200810007893A CN 101244137 B CN101244137 B CN 101244137B
- Authority
- CN
- China
- Prior art keywords
- injection
- preparation
- medicine
- above composition
- product
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention discloses a medicine for treating pneumonia and high/low fever as well as the preparation method, mainly comprising a Qingkailing injection, a ceftriaxone sodium for injection and an aminocaproic acid injection which are formed according to weight proportion. The medicine has the advantages of rapid curative effect and high healing rate in treating pneumonia as well as high/low fever.
Description
Technical field:
The present invention relates to a kind of pharmaceutical composition and preparation using method thereof for the treatment of pneumonia, belong to the Western medicine field.
Background technology:
Pneumonia is because the common frdquently encountered disease that bacterial infection, viral infection cause, the patient shows as asthma, breathes hard during outbreak, cough, hyperpyrexia or low grade fever do not move back.Azithromycin of Ying Yonging and andrographolide/Andrographolide antibacterium, antiviral curative effect are very good clinically, but because azithromycin and andrographolide pharmaceutical dosage form are simple, the side effect that often occurs in the use is bigger, and the untoward reaction to liver, kidney and blood system simultaneously also is difficult to eliminate.
Summary of the invention:
Therefore people treat pneumonia preferably to curative effect, and there is great demand in the medicine that has no side effect, does not also find the relevant report of relevant pharmaceutical composition of the present invention up to now.The inventor is through research repeatedly, and the checking repeatedly by animal and clinical trial, found finally the treatment of better curative effect pneumonia and hyperpyrexia are arranged, pharmaceutical composition that low grade fever does not move back, thereby finished the present invention.
Purpose of the present invention just provides a kind of pharmaceutical composition that pneumonia and hyperpyrexia, low grade fever do not move back for the treatment of, and the present invention also provides the compound method of described pharmaceutical composition.
Medicament selection QINKAILING ZHUSHEYE of the present invention, ceftriaxone for inj, amikacin sulfate injection, aminophenazone, 5% sucrose solution injection and 5% sugar-salt-water injection make up, make each efficacy of drugs produce synergism these drug regimens, thereby can effectively treat pneumonia and hyperpyrexia, low grade fever does not move back.Wherein: QINKAILING ZHUSHEYE: English name: Qing kai ling injection.Prescription source: drug standard-Chinese traditional patent formulation standard preparation 1998.Effect: heat-clearing and toxic substances removing, eleminating phlegm and freeing channels, consciousness and resuscitation restoring.Main component: cholic acid, Concha Margaritifera, Hyodeoxycholic Acid, Fructus Gardeniae, Cornu Bubali, Radix Isatidis, baicalin, Flos Lonicerae.Character: this product is pale brown color or henna clear liquid.Function with cure mainly: heat-clearing and toxic substances removing, eleminating phlegm and freeing channels, consciousness and resuscitation restoring.Be used for calentura coma, apoplectic hemiplegia, obnubilation.Also can be used for acute and chronic hepatitis, hepatitis B, upper respiratory tract infection, pneumonia, hyperpyrexia, and cerebral thrombosis, cerebral hemorrhage are seen above-mentioned patient.Specification: (1) 2ml: baicalin 10mg; Total ammonia 5mg (2) 5ml: baicalin 25mg; Total nitrogen 12.5mg (3) 10ml: baicalin 50mg; Total nitrogen 25mg.Pharmacological action: mainly contain antiinflammatory, analgesic, the liver protecting improves cerebral circulation, reduces the blood specific viscosity, promotes the absorption of brain necrosis tissue to wait effect.(1) antiinflammatory: (1) this product gastric infusion can obviously improve Turnover of Mouse Peritoneal Macrophages phagocytic rate and phagocytic index, can increase the release of rat abdominal cavity polymorphonuclear leukocyte (PMN) H2O2 amount.Illustrate: QINKAILING ZHUSHEYE can not only improve phagocytic activity and can strengthen oxidation disinfection ability in the cell.(2) the external lymphocyte under phytohaemagglutinin (PHA) stimulates cultivates and 3H-TDR mixes, and has observed the influence of QINGKAILING to normal rabbits and human T lymphocyte's mitosis reaction, shows that QINGKAILING has the inhibitory action of tangible dependent dose to this reaction.It is 22.53 μ l that its half effectively suppresses dosage (ED50), and disclosing QINGKAILING is a kind of strong T cytostatics.May be one of valuable pharmacological mechanism of immune inflammation illness such as clinical treatment hepatitis and uveitis.(2) analgesic: the administration of (1) this product ear vein has refrigeration function to rabbit by the heating that typhoid fever, paratyphoid fever first and second vaccines cause.(2) this product intravenously administrable has tangible refrigeration function to endotoxin-induced fever in rabbits.Middle the increasing of cAMP content of cerebrospinal fluid (CSF) that leukocytic pyrogen (LP) is caused has inhibitory action.Think that its analgesic mechanism may be after this medicine enters in the body, suppress the generation of FOAH district neuron cAMP, thereby move on the inhibition body temperature set point and reach and separate heat effect by some link.(3) the liver protecting: (1) this product gives rat skin lower injection 1ml/ every day only, and experimental carbon tetrachloride hepatic injury is had protective effect, can reduce the rising of blood ammonia nitrogen, blood urea nitrogen and blood lactic acid that carbon tetrachloride hepatic injury causes, recovers liver function.(2) this product is given rat skin lower injection, 1ml/ of every day, and totally 2 times, to the reduction effect being arranged by the hurried rising of the caused glutamate pyruvate transaminase of carbon tetrachloride acute liver damage.Can promote liver protein synthetic, rising rat blood serum mucin.(3) in the rat body, duplicate the variation that the toxic hepatitis pathological model has been observed general tissue with carbon tetrachloride, the variation of nucleic acid and protein, mitochondrion and redox enzymes thereof, hydrolase thinks that QINGKAILING has certain promotion repair to toxic hepatitis.(4) improve cerebral circulation, promote the brain necrosis tissue to absorb: (1) this product was put to death inspection with rabbit to experimental cephalophyma rabbit lumbar injection (dosage is the 2.6ml/kg body weight) after 11 days, 16 days, this product has the effect that promotes that local cephalophyma absorbs and repairs.Improve the local blood circulation obstacle of surrouding brain tissue, promote to absorb.The hypertrophy and the activate the phagocytic capacity of pointing out this medicine can promote the cephalophyma peripheral glia cell from histopathology strengthen, and quicken the hematoma repair process.(2) use the cranium computed tomography brain scan QINKAILING ZHUSHEYE treatment patients with cerebral hemorrhage 26 examples are treated the front and back paired observation, find its liquefaction absorbance 96.74%, hematoma complete obiteration person accounts for 76.92%.Show that QINKAILING ZHUSHEYE can promote intracranial hematoma liquefaction to absorb, and alleviates cerebral edema.(5) anticoagulant: QINKAILING ZHUSHEYE shows tame rabbit ear vein administration experimental result, to the significantly reduction effect of coagulation grade of blood plasma.The inductive platelet aggregation of ADP there is special significant inhibitory effect.(6) reduce the blood specific viscosity: to rat tail vein injection 0.3-0.6ml/100g body weight, can improve the caused high state of aggregation of macromole dextran with QINKAILING ZHUSHEYE.Reduce whole blood circle round viscosity, whole blood contrast viscosity hematocrit.Prothrombing, thrombin time prolong, and erythrocyte electrophoretic time is accelerated.With quiet of QINGKAILING 40ml, day 1 time, be 28 the course of treatment, treatment apoplexy 16 examples, carry out the blood examination result respectively before and after the treatment and show that QINGKAILING has clear improvement to paralytic's whole blood contrast viscosity, plasma viscosity, hematocrit, can also significantly shorten erythrocyte electrophoretic time.(7) LPO inhibitor: QINKAILING ZHUSHEYE has the obvious suppression effect to the generation of Medulla Leporis seu Oryctolagi homogenate lipid peroxide.In vitro tests, when drug level was 37.2mg/ml, suppression ratio was 80.57%.QINGKAILING can stop or reduce the carrying out of the chain oxidation reaction of radical pair brain tissue cell film unsaturated fatty acid, is very useful to the 26S Proteasome Structure and Function of protecting cell membrane.(8) reduce erythrocyte membrane fluidity: paralytic's erythrocyte membrane fluidity is higher than normal old people, and the paralytic adds quiet of 10% Glucose Liquid 500ml with QINKAILING ZHUSHEYE 40-60ml, day 1 time, shared 28 days, the check of drawing blood on an empty stomach early morning.Paralytic's mobility of erythrocyte membrance can be reduced to normal old man's matched group level.The reduction of cell membrane fluidity can make the mobility of memebrane protein increase, and helps various membrane receptors and aglucon such as hormone, medicine etc. in conjunction with the performance biological effect.Cell membrane fluidity reduces the barrier function that helps adjusting film.(9) reduce copper content and copper zinc ratio in paralytic's blood plasma: copper content and copper zinc ratio are apparently higher than normal old people's matched group in paralytic's blood plasma.Through QINKAILING ZHUSHEYE treatment 2-4 week, copper content and copper zinc ratio obviously descend in patient's blood plasma, recover and approaching normal old people's matched group level.
Ceftriaxone for inj: English name: Ceftriaxone Sodium for Injection; This product Main Ingredients and Appearance is a ceftriaxone sodium, its chemistry (6R by name, 7R)-and 7-[[(2-amino-4-thiazolyl) (methoxyimino) acetyl] amino]-8-oxo-3-[[(1,2,5,6-tetrahydrochysene-2-methyl-5,6-dioxo-1,2,4-triazine-3-yl) sulfo-] methyl]-5-sulfo--1-azabicyclo [4.2.0] oct-2-ene-2-carboxylic acid disodium salt three sesquialter hydrates.
Its structural formula is:
Molecular formula: C18H16N8Na2O7S33 H2O
Molecular weight: 661.59
Character: this product is white or off-white color crystalline powder; Odorless.Pharmacological toxicology: this product is long-acting, broad-spectrum cephalosporin, has very strong bactericidal action.Ceftriaxone sodium has the height antibacterial activity to following gram negative bacilli, enterobacteriaceae lactobacteriaceae and hemophilus influenzas such as escherichia coli, klebsiella, proteus mirabilis, the positive Bacillus proteus of indole, Salmonella, shigella; This product also has good antibacterial action to Gram-negative coccus such as meningococcus, gonococcuss; Gram-positive cocci is as all presenting sensitivity to this product to streptococcus pneumoniae, micrococcus scarlatinae, Streptococcus viridans, bargen's streptococcus etc.; Ceftriaxone also has certain antibacterial action to golden Portugal bacterium, but the more above-mentioned gram-positive cocci of its effect is for poor.Bacillus pyocyaneus, acinetobacter calcoaceticus etc. are poor to the sensitivity of this product.Indication: to the pathogenic microbial infection of this product sensitivity, as: pyemia, meningitis, dissemination Lyme disease (late period early), abdominal infection (peritonitis, biliary tract and gastrointestinal infection), bone, joint, soft tissue, skin and wound infection, immunologic hypofunction patient's infection, kidney and urinary tract infection, respiratory tract infection, especially pneumonia, otorhinolaryngology infection, genital system infection, comprise prevention infection before the gonorrhea, art.
Amikacin sulfate injection: its common name: amikacin sulfate injection.Chemical name is: O-3-amino-3-deoxidation-a-D-Glucopyranyl-(1 → 6)-O-[6-amino-6-deoxidation-a-D-Glucopyranyl-(1 → 4)]-N-(4-amino-2-hydroxyl-1-oxygen-butyl)-2-deoxidation-D-streptamine sulfate.English name: Kanamycin A Sulfate Sulfate Injection.Medicine classification: aminoglycosides.Indication: this product is applicable to severe infections due to responsive gram negative bacilli such as Pseudomonas aeruginosa and part other pseudomonass, escherichia coli, Proteus, Klebsiella, Enterobacter, Serratia, acinetobacter and the staphylococcus (methicillin-sensitivity strain), as bacteremia or septicemia, bacterial endocarditis, lower respiratory infection, bone joint infection, biliary tract infection, abdominal cavity infection, complexity urinary tract infection, skin soft-tissue infection etc.Because this product is stable to most aminoglycoside inactive enzymes, so be particularly useful for treating gram negative bacilli to the severe infections due to kanamycin, gentamycin or the tobramycin Resistant strain.Character: this product is colourless or yellowish clear liquid.Pharmacological toxicology: amikacin sulfate is a kind of aminoglycoside antibiotics.This product is to most enterobacteriaceae lactobacteriaceaes, as equal tool good action such as escherichia coli, Klebsiella, Enterobacter, Proteus, Shigella, Salmonella, citrobacter genus, Serratia, Pseudomonas aeruginosa and other pseudomonass of part, acinetobacter, alcaligenes etc. also there is good action; To the also better antibacterial action of tool of meningococcus, gonococcus, hemophilus influenza, yersinia's genus, campylobacter fetus, tubercule bacillus and some Mycobacterium, its antibacterial activity is lower slightly than gentamycin.The advantage that this product is the most outstanding is that the aminoglycoside inactive enzyme that many intestinal gram negative bacillis are produced is stable, not class enzymatic inactivation and lose antibacterial activity for this reason.In present 12 kinds of inactive enzymes that are separated to, this product only can be the passivation of AAC (6 ') institute, and AAD (4 ') and APH (3 ')-III can cause antibacterial to this product moderate drug resistance by chance in addition.Still responsive in the clinical isolating enterobacteriaceae lactobacteriaceae to about 60～70% pairs of this product of aminoglycoside drug resistance person such as gentamycin, tobramycin and netilmicins.In the gram negative bacilli amikacin Resistant strain also had in recent years and increase.This product is except that having the good antibacterial action methicillin-sensitivity strain in the staphylococcus in the gram positive coccus, and streptococcus pneumoniae, each group B streptococcus and Enterococcus are to big many drug resistances.This product is invalid to anaerobe.This product mechanism of action is the 30S subunit that acts on bacterial ribosome, suppresses the antibacterial synthetic protein.Amikacin and semi-synthetic penicillins or cephalosporins often share can obtain synergetic antibacterial effect.Pharmacokinetics: amikacin is oral seldom to be absorbed.Be absorbed rapidly after the intramuscular injection.Mainly be distributed in extracellular fluid, the part medicine can be distributed to various tissues, and can put aside in kidney cortex cell and interior ear fluid; But the concentration in heart auricle tissue, pericardial fluid, muscle, fat and interstitial fluid is very low.Concentration is low in bronchial secretion, bile and the aqueous humor.Protein binding rate is low.Not metabolism in vivo.Is adult blood eliminated half-life (t1/2?) be 2～2.5 hours.Can see through Placenta Hominis and enter fetal tissue.Concentration is low in the cerebrospinal fluid.Mainly discharge, discharge more than 90% in 24 hours after the administration through glomerular filtration.Hemodialysis and peritoneal dialysis can be removed the medicine of a great deal of in blood.Usage and dosage: 1. be grown up intramuscular injection or intravenous drip.Simple property urinary tract infection is to per 12 hours 0.2g of antimicrobial drug drug resistance person commonly used; Be used for per 12 hours 7.5mg/kg of other systemic infection, or per 24 hours 15mg/kg.Being grown up was no more than a 1.5g in, was no more than 10 days the course of treatment.2. children's, intramuscular injection or intravenous drip.Press body weight 10mg/kg for first dose, continue with per 12 hours 7.5mg/kg, or per 24 hours 15mg/kg.3. the renal function patient of going down: creatinine clearance rate＞50～90ml/min person gave 60～90% of normal dose (7.5mg/kg) in per 12 hours; Per 24～48 hours of creatinine clearance rate 10～50ml/min person is with 20～30% of 7.5mg/kg.Creatinine clearance rate can directly be measured or be calculated as follows from the serum creatinine value: adult male creatinine clearance rate=(140-age) * standard body weight (kg)/72 * patient serum creatinine concentration (mg/dl) or (140-age) * standard body weight (kg)/50 * patient serum creatinine concentration (mg/dl); Adult female's creatinine clearance rate=(140-age) * standard body weight (kg) * 0.85/72 * patient serum creatinine concentration (mg/dl) or (140-age) * standard body weight (kg) * 0.85/50 * patient serum creatinine concentration (mg/dl).Contraindication: to amikacin or other aminoglycosides patient's forbidding hypersensitive.Points for attention: 1. cross allergy, may be also irritated to a kind of aminoglycoside patient hypersensitive to other aminoglycosides.2. should note carrying out following inspection in the medication process: (1) routine urinalysis and renal function are measured, to prevent the severe renal toxic reaction.(2) the high frequency hearing impairment is especially noted in hearing test or tin electrograph inspection, and this is particularly important to the gerontal patient.3. should monitor blood drug level when having ready conditions in the course of treatment, especially neonate, old age and the renal function patient of going down.Should the about peak concentration of administration 7.5mg/kg person blood remain on 15～30 in per 12 hours? g/ml, paddy concentration 5～10? g/ml; Should 1 time on the one administration 15mg/kg person blood peak concentration of drug maintain 56～64? g/ml, paddy concentration should be＜and 1? g/ml.4. following situation Ying Shen this product: (1) dehydration can make blood drug level increase, easily toxigenicity reaction.(2) the 8th pairs of cranial nerve infringements are because of this product can cause vestibular nerve and Auditory nerve impairment.(3) myasthenia gravis or parkinson disease because of primary disease can cause the neuromuscular blockade effect, cause the skeletal muscle weakness.(4) renal function injury person is because of this product has nephrotoxicity.5. the interference this product to diagnosis can make the measured value of alanine aminotransferase (ALT), Aspartic Acid aminotransferase (AST), serum bilirubin level and lactic dehydrogenase enzyme concentration increase; The measured value of blood calcium, magnesium, potassium, na concn may reduce.6. aminoglycoside can cause mutual inactivation with beta-lactam class (cephalosporins and penicillins) when mixing.Must divide bottle to instil when this product and above-mentioned antibiotic use in conjunction.Amikacin also should not instil with bottle with other drug.7. should give the patient enough moisture content, to reduce tubular injury.8. when preparing intravenous administration, every 500mg adds sodium chloride injection or 5% glucose injection or other sterilization diluents 100～200ml.The adult should slowly instil in 30～60 minutes, the corresponding minimizing of liquid measure of infant patients dilution.Drug interaction: 1. this product and other aminoglycosides share or successively continuous and local or whole body use, can increase ototoxicity, nephrotoxicity and neuromuscular blockade effect.2. this product and neuromuscular blocking drug share and can increase the weight of the neuromuscular blockade effect, cause symptoms such as infantile myasthenia is weak, respiration inhibition.This product and capreomycin, cisplatin, etacrynic acid, furosemide or vancomycin (or norvancomycin) etc. share, or continuous and local or whole body application successively, may increase ototoxicity and nephrotoxicity.3. this product and cefalotin or cefazolin part or whole body share and may increase nephrotoxicity.This product should not with injection compatibilities such as amphotericin B, cefalotin, sulfadiazine and tetracycline, in same bottle, do not instil.4. this product and polymyxins injection share or continuous and local or whole body application successively, can increase nephrotoxicity and neuromuscular blockade effect.5. other nephrotoxicity medicines and ototoxic drug all should not share with this product or successively use, in order to avoid increase the weight of nephrotoxicity or ototoxicity.
Aminophenazone: with the name: compound aminophenazone (not containing urethane).English name: CompoundAminophenazone.Indication: hyperpyrexia, headache, migraine, menstrual pain, myalgia, toothache and arthralgia etc.Composition: aminophenazone injection: every 2ml contains aminophenazone 0.1g, phenazone 0.04g, phenobarbital 0.018g (has data to be: barbital sodium 0.057g).The compound aminophenazone sheet: every contains aminophenazone 0.02g, phenacetin 0.2g, phenobarbital 0.005g.Usage and dosage: the subcutaneous or intramuscular injection of being grown up, 2ml/ time, but duplicate injection in case of necessity, but be no more than 10ml/ day.The child is cut down according to the circumstance.Effect: have analgesic, analgesia, antiinflammation.Untoward reaction: excessive a large amount of diaphoresis, vomiting, pulse quickening, erythra, heating, the stomatitis of easily causing of consumption, serious granulocytopenia and aplastic anemia can also take place in a few patients.Points for attention: existing application separately only is used for some compound preparation.The project that should check or monitor when medication front and back and medication: be only limited to short-term and use, 1 week should make regular check on hemogram as surpassing.Other explanation: other title: aminophenazone-phenacetin-phenobarbital, aminophenazone/phenacetin/phenobarbital, An Jibilin/phenacetin/phenobarbital, antondin Amidopyrine, AminophenazoneCompound, Antodin
Pharmaceutical composition of the present invention has antiinflammatory, analgesic; protection lung, spleen, liver; improve cerebral circulation; reduce effects such as blood specific viscosity; be used for dense toxemia, meningitis, skin of soft tissue and wound infection, kidney and urinary tract infection, respiratory tract infection, especially pneumonia, otorhinolaryngology infection, genital system infection have specially good effect.
Also to be the inventor through a large amount of groping sum up amount of drug of the present invention draws, and each amounts of components all has curative effect preferably in following weight range.
QINKAILING ZHUSHEYE: 18-22ml
Ceftriaxone for inj: 1-3g
Amikacin sulfate injection: 0.5-1.5g
Aminophenazone injection: 1-2ml
5% sucrose solution injection: 500-750ml
5% sugar-salt-water injection: 250-500ml
For reaching better therapeutic, the preferable amount of each component is QINKAILING ZHUSHEYE 20ml, ceftriaxone for inj 3g, amikacin sulfate injection 1.5g, aminophenazone injection 2ml, 5% sucrose solution injection 500ml, 5% sugar-salt-water injection 250ml.
The specific embodiment:
Below in conjunction with embodiment the technical scheme that the present invention prepares is described.
The preparation of [embodiment 1] injection
A: QINKAILING ZHUSHEYE 18ml, 5% sucrose solution injection 200ml: above composition is mixed, and the preparation of the preparation method of injection promptly routinely.
B: ceftriaxone for inj 1g, 5% sugar-salt-water injection 200ml: above composition is mixed, and the preparation of the preparation method of injection promptly routinely.
C: amikacin sulfate injection 0.5g, 5% sucrose solution injection 200ml: above composition is mixed, and the preparation of the preparation method of injection promptly routinely.
D: aminophenazone injection 1ml.
The preparation of [embodiment 2] injection
A: QINKAILING ZHUSHEYE 20ml, 5% sucrose solution injection 250ml: above composition is mixed, and the preparation of the preparation method of injection promptly routinely.
B: ceftriaxone for inj 2g, 5% sugar-salt-water injection 250ml: above composition is mixed, and the preparation of the preparation method of injection promptly routinely.
C: amikacin sulfate injection 1g, 5% sucrose solution injection 250ml: above composition is mixed, and the preparation of the preparation method of injection promptly routinely.
D: aminophenazone injection 1.5ml.
The preparation of [embodiment 3] injection
A: QINKAILING ZHUSHEYE 22ml, 5% sucrose solution injection 250ml: above composition is mixed, and the preparation of the preparation method of injection promptly routinely.
B: ceftriaxone for inj 3g, 5% sugar-salt-water injection 250ml: above composition is mixed, and the preparation of the preparation method of injection promptly routinely.
C: amikacin sulfate injection 1.5g, 5% sucrose solution injection 250ml: above composition is mixed, and the preparation of the preparation method of injection promptly routinely.
D: aminophenazone injection 2ml.
Below further set forth the beneficial effect of medicine of the present invention by testing example, these tests comprise that the pharmacodynamics test of medicine of the present invention and clinical observation test.
[test example 1] pharmacodynamics test checking is as follows:
Causing the pneumonia model mice with antibacterial is experimental animal, mixes tail vein injection administration 5ml/kg successively with medicine A of the present invention, B, C respectively hereinafter to be referred as QINGKAILING, treats test grouping, 30 every group 7 days.Statistics survival rate and mortality rate, and establish not administration group and organize in contrast.Result of the test is as follows:
The clinical treatment effect observations of [test example 2] medicine of the present invention
1, physical data
Accept outpatient service out-patient 296 examples for medical treatment, wherein male 169 examples, women 127 examples, 7 years old of age minimum, maximum 81 years old.
2, diagnostic criteria
Light-duty pneumonia: the patient fell ill about half a year, chest pain, uncomfortable in chest, rapid breathing cough, myasthenia of limbs, tired, weakness of QI.
Heavy pneumonia: medical history is more than 1 year, patient's chest pain, and the symptom of feeling oppressed is obvious, and it is unable to pant, emaciation and sallow complexion, dyspnea.
3, Therapeutic Method
1. first intramuscular injection aminophenazone 2ml.
2. intravenous drip A group QINKAILING ZHUSHEYE, B organize ceftriaxone for inj successively respectively according to quantity again, C organizes amikacin sulfate injection, once a day, logotype three days, the same day is effective, cures in 3rd.
4, efficacy assessment standard
Produce effects: symptom rapidly disappears, and physical recovery is normal, follows up a case by regular visits to 1-3 and does not have recurrence.
Take a turn for the better: patient's chest pain, sx uncomfortable in chest, respiratory frequency drops to 22 times by surplus 40 times, and partial pressure of oxygen raises, and the X sheet shows that the lung interstitial lung inflammation obviously improves, and absorbs rapidly.
Invalid: as not reach improvement standard person.
5, therapeutic outcome: see the following form:
| Disease name | Case load | Therapeutic outcome | Total effective rate % | ||
| Produce effects | Take a turn for the better | Invalid | |||
| Bacterial pneumonia | 165 | 152 | 11 | 2 | 98.7 |
| Viral pneumonia | 131 | 119 | 8 | 4 | 96.9 |
In 3 days treatment, with Drug therapy bacterial pneumonia 165 people of the present invention, produce effects 152 people wherein, 11 people that take a turn for the better, invalid 2 people, total effective rate is 98.7%; Viral pneumonia 131 people, produce effects 119 people wherein, 8 people that take a turn for the better, invalid 4 people, total effective rate is 96.9%.
Claims (4)
1. treat the composition of medicine that pneumonia and hyperpyrexia, low grade fever do not move back for one kind, it is characterized in that: form by following four part medicines, A: QINKAILING ZHUSHEYE 18ml, 5% sucrose solution injection 200ml, its preparation method mix above composition, and the preparation of the preparation method of injection promptly routinely; B: ceftriaxone for inj 1g, 5% sugar-salt-water injection 200ml: above composition is mixed, and the preparation of the preparation method of injection promptly routinely; C: amikacin sulfate injection 0.5g, 5% sucrose solution injection 200ml: above composition is mixed, and the preparation of the preparation method of injection promptly routinely; D: aminophenazone injection 1ml.
2. treat the composition of medicine that pneumonia and hyperpyrexia, low grade fever do not move back for one kind, it is characterized in that: form by following four part medicines, A: QINKAILING ZHUSHEYE 20ml, 5% sucrose solution injection 250ml, its preparation method mix above composition, and the preparation of the preparation method of injection promptly routinely; B: ceftriaxone for inj 2g, 5% sugar-salt-water injection 250ml: above composition is mixed, and the preparation of the preparation method of injection promptly routinely; C: amikacin sulfate injection 1g, 5% sucrose solution injection 250ml: above composition is mixed, and the preparation of the preparation method of injection promptly routinely; D: aminophenazone injection 1.5ml.
3. treat the composition of medicine that pneumonia and hyperpyrexia, low grade fever do not move back for one kind, it is characterized in that: form by following four part medicines, A: QINKAILING ZHUSHEYE 22ml, 5% sucrose solution injection 250ml, its preparation method mix above composition, and the preparation of the preparation method of injection promptly routinely; B: ceftriaxone for inj 3g, 5% sugar-salt-water injection 250ml: above composition is mixed, and the preparation of the preparation method of injection promptly routinely; C: amikacin sulfate injection 1.5g, 5% sucrose solution injection 250ml: above composition is mixed, and the preparation of the preparation method of injection promptly routinely; D: aminophenazone injection 2ml.
4. as claim 1 or the 2 or 3 described composition of medicine purposes in the medicine that preparation treatment pneumonia and hyperpyrexia, low grade fever do not move back.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2008100078937A CN101244137B (en) | 2008-02-28 | 2008-02-28 | Medicament for treating pulmonitis, and high fever, lower fever, and preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2008100078937A CN101244137B (en) | 2008-02-28 | 2008-02-28 | Medicament for treating pulmonitis, and high fever, lower fever, and preparation method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101244137A CN101244137A (en) | 2008-08-20 |
| CN101244137B true CN101244137B (en) | 2011-05-04 |
Family
ID=39944958
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2008100078937A Expired - Fee Related CN101244137B (en) | 2008-02-28 | 2008-02-28 | Medicament for treating pulmonitis, and high fever, lower fever, and preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101244137B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109260329A (en) * | 2018-11-02 | 2019-01-25 | 云南康创生物医药科技孵化有限公司 | A kind of anti-cold pharmaceutical composition and preparation method thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1285355A (en) * | 1999-08-19 | 2001-02-28 | 中国石油化工集团公司 | Cyclopentadiene titanium compound |
| CN1597684A (en) * | 2003-09-16 | 2005-03-23 | 广州白云山制药股份有限公司 | Sodium ceftriaxone and its preparation method |
| CN1843329A (en) * | 2006-05-17 | 2006-10-11 | 天津生机集团有限公司 | Compound amikacin sulfate injection for animal and its preparation method |
| CN1887255A (en) * | 2006-07-27 | 2007-01-03 | 天津生机集团有限公司 | Compound taurine injection and its prepn process and use |
-
2008
- 2008-02-28 CN CN2008100078937A patent/CN101244137B/en not_active Expired - Fee Related
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1285355A (en) * | 1999-08-19 | 2001-02-28 | 中国石油化工集团公司 | Cyclopentadiene titanium compound |
| CN1597684A (en) * | 2003-09-16 | 2005-03-23 | 广州白云山制药股份有限公司 | Sodium ceftriaxone and its preparation method |
| CN1843329A (en) * | 2006-05-17 | 2006-10-11 | 天津生机集团有限公司 | Compound amikacin sulfate injection for animal and its preparation method |
| CN1887255A (en) * | 2006-07-27 | 2007-01-03 | 天津生机集团有限公司 | Compound taurine injection and its prepn process and use |
Non-Patent Citations (1)
| Title |
|---|
| CN 1887255 A,全文. |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101244137A (en) | 2008-08-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Michalopoulos et al. | The revival of fosfomycin | |
| Carmine et al. | Cefotaxime: a review of its antibacterial activity, pharmacological properties and therapeutic use | |
| Falagas et al. | Fosfomycin: use beyond urinary tract and gastrointestinal infections | |
| Crowther et al. | Combination chemotherapy using L-asparaginase, daunorubicin, and cytosine arabinoside in adults with acute myelogenous leukaemia | |
| Mertin et al. | Unsaturated fatty acids in multiple sclerosis. | |
| Fiaccadori et al. | Colistin use in patients with reduced kidney function | |
| Giua et al. | Colistin bladder instillation, an alternative way of treating multi-resistant Acinetobacter urinary tract infection: a case series and review of literature | |
| US20220362354A1 (en) | Wide-spectrum antibacterial pharmaceutical formulations comprising lysozyme and methods of using the same | |
| Miller et al. | Do antibiotics cause mitochondrial and immune cell dysfunction? A literature review | |
| CN101244137B (en) | Medicament for treating pulmonitis, and high fever, lower fever, and preparation method | |
| Majewski | A current opinion on the safety and efficacy of doxycycline including parenteral administration–A review | |
| EP0446069A1 (en) | Treatment of Clostridium difficile diarrhoea and pseudomembranous colitis | |
| Anderson | Fusidic acid: new opportunities with an old antibiotic. | |
| Suarez-de-la-Rica et al. | Severe cefepime-induced status epilepticus treated with haemofiltration | |
| JP3884611B2 (en) | Improving agent for impulsive disease | |
| KR101965591B1 (en) | Composition for inhibiting activity of amylase containing chitooligosaccharide | |
| CN101612155A (en) | Remove the method for gram negative bacilli with the piperacillin tazobactam compound preparation | |
| JP2006206474A (en) | Functional food and medicine | |
| CN111184867A (en) | Chemical medicine composition for treating helicobacter pylori infection | |
| RU2614730C1 (en) | Antibacterial agents and method for treating intestinal yersiniosis or pseudotuberculosis, or colibacillosis | |
| Carlson | Antibiotics and pharmacotherapeutics in the neonate | |
| CN101549049B (en) | Chinese medicinal combination for treating acute nephritis and chronic nephritis | |
| CN101342187B (en) | Medicament composition for treating dysentery | |
| Manappallil et al. | Hypokalemia myopathy due to Piperacillin-tazobactam induced resistant hypokalemia | |
| Zhao et al. | Effects of low-molecular-weight polyguluronate sulfate on experimental urolithiasis in rats |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20110504 Termination date: 20120228 |